Serum Magnesium Is Associated with Long-Term Survival of Non-ST-Elevation Myocardial Infarction Patients.
NSTEMI
endothelial dysfunction
magnesium
mortality
prognosis
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
09 Oct 2023
09 Oct 2023
Historique:
received:
24
09
2023
revised:
05
10
2023
accepted:
07
10
2023
medline:
23
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Low serum magnesium (sMg) is associated with cardiovascular risk factors and atherosclerotic disease. To evaluate the association between sMg levels on admission and clinical outcomes in hospitalized non-ST-elevation myocardial infarction (NSTEMI) patients. A retrospective analysis of all patients admitted to a single tertiary center with a primary diagnosis of NSTEMI. Patients with advanced chronic kidney disease were excluded. Clinical data were collected and compared between lower sMg quartile patients (Q1; sMg < 1.9 mg/dL) and all other patients (Q2-Q4; sMg ≥ 1.9 mg/dL). The study cohort included 4552 patients (70% male, median age 69 [IQR 59-79]) who were followed for a median of 4.4 (IQR 2.4-6.6) years. The median sMg level in the low sMg group was 1.7 (1.6-1.8) and 2.0 (2.0-2.2) mg/dL in the normal/high sMg group. The low sMg group was older (mean of 72 vs. 67 years), less likely to be male (64% vs. 72%), and had higher rates of comorbidities, including diabetes, hypertension, and atrial fibrillation (59% vs. 29%, 92% vs. 85%, and 6% vs. 5%; Low sMg is independently associated with higher risk of long-term mortality among patients recovering from an NSTEMI event.
Sections du résumé
BACKGROUND
BACKGROUND
Low serum magnesium (sMg) is associated with cardiovascular risk factors and atherosclerotic disease.
OBJECTIVE
OBJECTIVE
To evaluate the association between sMg levels on admission and clinical outcomes in hospitalized non-ST-elevation myocardial infarction (NSTEMI) patients.
METHODS
METHODS
A retrospective analysis of all patients admitted to a single tertiary center with a primary diagnosis of NSTEMI. Patients with advanced chronic kidney disease were excluded. Clinical data were collected and compared between lower sMg quartile patients (Q1; sMg < 1.9 mg/dL) and all other patients (Q2-Q4; sMg ≥ 1.9 mg/dL).
RESULTS
RESULTS
The study cohort included 4552 patients (70% male, median age 69 [IQR 59-79]) who were followed for a median of 4.4 (IQR 2.4-6.6) years. The median sMg level in the low sMg group was 1.7 (1.6-1.8) and 2.0 (2.0-2.2) mg/dL in the normal/high sMg group. The low sMg group was older (mean of 72 vs. 67 years), less likely to be male (64% vs. 72%), and had higher rates of comorbidities, including diabetes, hypertension, and atrial fibrillation (59% vs. 29%, 92% vs. 85%, and 6% vs. 5%;
CONCLUSIONS
CONCLUSIONS
Low sMg is independently associated with higher risk of long-term mortality among patients recovering from an NSTEMI event.
Identifiants
pubmed: 37836583
pii: nu15194299
doi: 10.3390/nu15194299
pmc: PMC10574643
pii:
doi:
Substances chimiques
Magnesium
I38ZP9992A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Circ Genom Precis Med. 2019 Jan;12(1):e002349
pubmed: 30645173
Am Heart J. 1998 Sep;136(3):480-90
pubmed: 9736141
Kidney Int. 2014 Jan;85(1):174-81
pubmed: 23986148
Circ Res. 1990 Sep;67(3):645-50
pubmed: 1697793
Magnesium. 1988;7(5-6):300-5
pubmed: 3075246
Nutrients. 2016 Sep 19;8(9):
pubmed: 27657115
Thromb Haemost. 1979 Aug 31;42(2):603-10
pubmed: 505367
Am Heart J. 2000 Aug;140(2):212-8
pubmed: 10925332
J Am Coll Cardiol. 1996 Jun;27(7):1771-6
pubmed: 8636567
Magnes Res. 2010 Jun;23(2):60-72
pubmed: 20353903
Am Heart J. 1984 Jul;108(1):188-93
pubmed: 6375330
Magnes Res. 2001 Dec;14(4):283-90
pubmed: 11794636
J Am Coll Nutr. 1995 Feb;14(1):71-9
pubmed: 7706615
Am J Cardiol. 2003 Sep 15;92(6):665-9
pubmed: 12972103
Clin Cardiol. 1988 Dec;11(12):824-8
pubmed: 3233812
J Cardiovasc Pharmacol Ther. 1996 Jul;1(3):243-254
pubmed: 10684423
Arch Intern Med. 1988 Nov;148(11):2415-20
pubmed: 3056314
Int J Epidemiol. 1999 Aug;28(4):645-51
pubmed: 10480691
Thromb Res. 1996 Sep 1;83(5):341-9
pubmed: 8873343
Am J Clin Nutr. 2007 Apr;85(4):1068-74
pubmed: 17413107
Eur J Nutr. 2022 Oct;61(7):3697-3706
pubmed: 35689124
Ann Thorac Surg. 1998 Apr;65(4):967-72
pubmed: 9564911
J Nutr. 2010 Mar;140(3):509-14
pubmed: 20089787
J Biol Chem. 1980 Dec 25;255(24):11688-93
pubmed: 6449512
Cardiovasc Res. 1997 Jun;34(3):453-63
pubmed: 9231028
BMC Med. 2018 May 17;16(1):68
pubmed: 29769070
Br J Anaesth. 2010 Jan;104(1):44-51
pubmed: 19933511
J Cardiovasc Pharmacol Ther. 2003 Sep;8(3):193-200
pubmed: 14506544
Stroke. 2004 Jan;35(1):22-7
pubmed: 14657448
Arch Intern Med. 1969 Sep;124(3):302-11
pubmed: 5806042
Magnes Res. 2021 May 1;34(2):84-89
pubmed: 34463286
Lancet. 2002 Oct 19;360(9341):1189-96
pubmed: 12401244
JACC Cardiovasc Interv. 2022 Oct 10;15(19):1977-1988
pubmed: 36202565
Am J Clin Nutr. 2011 Feb;93(2):253-60
pubmed: 21106914
Am J Med. 2013 Sep;126(9):825-31
pubmed: 23891286
Circulation. 1989 Mar;79(3):674-86
pubmed: 2917391
Circulation. 2000 Nov 7;102(19):2353-8
pubmed: 11067788
Clin Chim Acta. 2000 Apr;294(1-2):1-26
pubmed: 10727669
Clin J Am Soc Nephrol. 2007 Mar;2(2):366-73
pubmed: 17699436
Eur Heart J Acute Cardiovasc Care. 2022 Dec 27;11(12):922-930
pubmed: 36229932
Arch Intern Med. 1992 Nov;152(11):2189-96
pubmed: 1444677
Biochim Biophys Acta. 2004 May 24;1689(1):13-21
pubmed: 15158909
Nutrients. 2023 Apr 22;15(9):
pubmed: 37432174
FEBS Lett. 1992 Oct 26;311(3):187-91
pubmed: 1397313
J Am Coll Nutr. 1994 Oct;13(5):429-46
pubmed: 7836621
Clin Cardiol. 1993 Jun;16(6):493-6
pubmed: 8358883
Mayo Clin Proc. 2022 Jul;97(7):1247-1256
pubmed: 35787854
Am J Clin Nutr. 2013 Jul;98(1):160-73
pubmed: 23719551